![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
- Bagrete J.S., Lockwood G., Lopez-Bernal A., Barlow D.H. and Ledger W.L. (1998) Comparison of highly purified FSH (Metrodin-high purity) with pergonal for IVF superovulation. Journal of Assisted Reproduction and Genetics 15, 65-69.
- Balach J., Miro F., Burzaco I., Casamitjana R., Civico S., Ballesca J.I., Puerto B. and Vanrell J.A. (1995) The role of luteinizing hormone in human follicle development and longstanding hypogonadotropic hypogonodism and using recombinant human follicle stimulating hormone. Human Reproduction 10, 1678-1683.
- Billig H., Furuta I. and Hsueh A.J.W. (1994) Gonadotropin releasing hormone directly induces apoptotic cell death it the rat ovary: biochemical and in situ ribonucleic acid fragmentation in granuloca cells. Endocrinology 134, 245-252.
- Chappel S.C. and Howles C. (1991) Revaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Human Reproduction 6, 1206-1212.
- Coelingh Bennink H.C.T., Fanser B.C.J.M. and Out H.J. (1998) Recombinant follicle stimulating hormone (FSH; Purge) is more efficient than urinary FSH(Merton) in women with clomiphene citrate-resistant, normogonodopropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomised, clinical trial. Fertility and Sterility 69, 19-25.
- Diedrich K., Diedrich C., Santos E., Zoll C.,A1 Hasani Krebs D. and Klingmuller D., Reissmann T. (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotropin releasing hormone antagonist Cetrorelix during ovarian stimulation. Human Reproduction 9, 788-791.
- Fleming R., Chung C.C., Yates R.W. and Coutts J.R. (1996) Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Human Reproduction 11, 1854-1858.
- Fox R., Ekeroma A. and Wardle P. (1997) Ovarian response to purified FSH in infertile women with long-standing hypogonadotropic hypogonodism. Australian and New Zealand Journal of Obstetrics and Gynaecology 37, 92-94.
- Hornnes P., Giroud D., Howles C.M. and Loumaye E. (1993) Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion and pregnancy in a World Health Organisation group II anovulatory women. Fertility and Sterility 60, 724-726.
- Homburg R., Levy T. and Ben-Rafael Z. (1995) A comparative prospective study of a conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertility and Sterility 63, 729-733.
- Hurwitz A., Ebstein B., Palti Z., Har-Nir R and Ron M. (1986) The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone. Fertility and Sterility 46, 378-383.
- Kouichi A., Takahisa O., Joji Y., Akaboshi K., Oda T., Yoshida J., Kohriyama S., Miyazaki T. and Yoshimusa Y. (1998) The effects of gonadotropin releasing hormone agonist on androstanedione production and follicular development during controlled ovarian hyperstimulation. Journal of Assisted Reproduction and Genetics 15, 478-483.
- Loucopoulos A., Ferin M., Vande Wiele R.L., Dyrenfurlt I., Linbia D., Yeh M. and Jewelewicz R. (1984) Pulsatile administration of gonadotropin-releasing hormone for induction of ovulation. American Journal of Obstetrics and Gynecology 148, 895-900.
- Miller K.A., Patton G.W. and Queenan J.T. (1998) The performance of subcutaneously injected fertinex when used as the sole gonadotropin for in vitro, fertilisation stimulation. Fertility and Sterility 69, 658-664.
- Out H.J., Mannaerts B.M.J.L., Driessen S.G.A.J. and Coeling Bennink H.J.T. (1996) Recombinant follicle stimulating hormone(r-hFSH) in assisted reproduction: more oocytes, more pregnancies, results from five comparative studies. Human Reproduction Update 2, 162-171.
- Out H.J., Mannaerts B.M.J. Driessen S.G. and Bennink H.J. (1995) A prospective, randomised, assessor-blind, multicentre study comparing recombinant and urinary follicle -stimulating hormone (Puregon vs. Metrodin) in in-vitro, fertilisation. Human Reproduction 10, 2534-2540.
- Palermo R., Amodeo G., Navot D., Rosenwaks Z. and Cittadini E. (1988) Concomitant gonadotropin releasing hormone agonist and menotropin treatment for the synchronised induction of multiple follicles. Fertility and Sterility 49, 290-295.
- Remorgida V., Venturini P.L., Anserini P., Lanera P. and DeCecco L. (1989) Administration of pure follicle-stimulating hormone during gonadotropin-releasing hormone agonist therapy in patients with clomiphene-resistant polycystic ovarian disease: hormonal evaluations and clinical perspectives. American Journal of Obstetrics and Gynecology 160, 108-113.
- Weissman A., Merriano J., Ward S., Gotleib L and Caspar R.F. (1999) Intracytoplasmic sperm injection after follicle stimulation with highly purified human follicle stimulating hormone compared with human menopausal gonadotropin. Journal of Assisted Reproduction and Genetics 16, 63-68.
- Westergaard L.G., Erb K., Laursen S., Rasmussen P.E. and Rex S. (1996) The effect of human menopausal gonadotropin and highly purfied, urine-derived follicle-stimulating hormone on the outcome of in-vitro fertilisation in down-regulated normogonadotrophic women. Human Reproduction 11, 12091213.
Journal of Obstetrics and Gynaecology
Volume 21, 2001 - Issue 2